We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00618319
Recruitment Status : Completed
First Posted : February 20, 2008
Last Update Posted : October 2, 2015
Information provided by (Responsible Party):

Brief Summary:
This study will examine the effect of BIIB021 on GIST growth and metabolism.

Condition or disease Intervention/treatment Phase
GIST Drug: BIIB021 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
Study Start Date : February 2008
Primary Completion Date : April 2010
Study Completion Date : April 2010

Arm Intervention/treatment
Experimental: 1
Drug: BIIB021
Dose, schedule, and duration specified in protocol
Other Name: CNF2024

Primary Outcome Measures :
  1. Changes in FDG-PET imaging [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Characterize the safety profile of BIIB021 [ Time Frame: Duration of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  • Age greater than or equal to 18 years at the time of informed consent.
  • Pathologically confirmed GIST refractory to, intolerant of, or not a candidate for imatinib and sunitinib therapy.
  • FDG PET standard uptake value (SUVmax; averaged over a maximum of 5 lesions) greater than or equal to 2 at screening.
  • ECOG performance status of less than or equal to 2.
  • Lab values consistent with adequate renal hepatic and bone marrow function.
  • Must utilize effective contraception.

Exclusion Criteria:

  • Prior treatment with imatinib, sunitinib, or sorafenib with in 14 days of day 1.
  • Prior treatment with Hsp90 inhibitors at any time.
  • Prior antitumor therapies including prior experimental agents, approved antitumor small molecules (excluding imatinib, sunitinib, or sorafenib) and biologics, or radiotherapy with in 28 days or <3 half lives (whichever is longer) before start of BIIB021treatment.
  • Diabetes treated with insulin and/ or concurrent severe or uncontrolled other medical disease (i.e, systemic infection, hypertension, coronary artery disease, congestive heart failure).
  • History of/ or predisposition to seizures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00618319

United States, California
Reseach Facility
Encinitas, California, United States
Research Site
Santa Monica, California, United States, 90404
United States, Texas
Reseach Facility
San Antonio, Texas, United States
Sponsors and Collaborators
Study Director: Medical Director Biogen

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT00618319     History of Changes
Other Study ID Numbers: 120GS201
First Posted: February 20, 2008    Key Record Dates
Last Update Posted: October 2, 2015
Last Verified: March 2011

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases